CONSORCIO PARA LA EXPLOTACION DEL CENTRO NACIONAL DE ANALISIS GENOMICO

Their core work

Spain's National Centre for Genomic Analysis (CNAG) is a high-throughput sequencing and bioinformatics facility based in Barcelona that generates and analyzes large-scale genomic data. They specialize in single-cell genomics, multi-omics integration, and computational analysis for biomedical research — particularly rare diseases, cancer immunoprofiling, and haematological disorders. Their core value lies in providing sequencing infrastructure and advanced bioinformatic pipelines that enable consortium partners to decode complex biological datasets at scale.

What they specialise in

How they've shifted over time

In their earlier H2020 projects (2018–2019), CNAG focused on rare disease data infrastructure — building shared data platforms, enabling FAIR data access, and supporting European Reference Networks through expert-driven and data-driven approaches. From 2020 onward, their work shifted decisively toward multi-omics integration, machine learning, and predictive modeling across a broader range of diseases including haematological cancers, inflammatory conditions, and even food-related microbiome research. This evolution reflects a transition from genomic data provider to computational genomics partner capable of AI-driven biological interpretation.

CNAG is moving rapidly toward machine learning and federated analysis of multi-omics data, positioning them as a go-to partner for any consortium needing AI-powered genomic interpretation at scale.

How they like to work

CNAG operates predominantly as a specialist partner, contributing sequencing and bioinformatics capabilities to large European consortia — 9 of their 10 projects are as participant. Their single coordinator role (BCLLatlas, an ERC Synergy Grant worth EUR 2.3M) demonstrates they can lead ambitious research when the topic aligns with their core genomics expertise. With 320 unique partners across 37 countries, they function as a well-connected infrastructure hub that many different consortia rely on for genomic analysis capacity.

CNAG has collaborated with 320 unique partners across 37 countries, giving them one of the broadest networks in European genomics research. Their partnerships span clinical centres, universities, biobanks, and computational labs across virtually all EU member states and associated countries.

What sets them apart

CNAG brings national-scale sequencing infrastructure combined with growing computational and AI capabilities — a combination that is rare among European genomics centres, which typically specialize in one or the other. Their participation across rare diseases, cancer, inflammatory disorders, and even agricultural genomics shows unusual versatility for a sequencing centre. For consortium builders, they offer a proven track record of delivering high-throughput molecular data within complex multi-partner projects, backed by Spain's national genomics mandate.

Highlights from their portfolio

• BCLLatlas
  Their only coordinator role and largest single grant (EUR 2.3M ERC Synergy Grant), mapping B-cell transformation to leukemia using single-cell genomics — a flagship project showcasing their core capability.
• 3TR
  Their second-largest funding (EUR 1.2M) in a major multi-omics initiative to understand treatment non-response in autoimmune diseases, reflecting their growing role in translational medicine.
• SCREEN4CARE
  Combines newborn genetic screening with AI-driven digital tools for rare disease diagnosis — represents their convergence of genomics infrastructure with machine learning applications.